Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lumateperone Tosylate

FDA-approved product (capsule, oral), marketed as Caplyta.

Registered studies
6
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Lumateperone Tosylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Psychosis
  • Schizophrenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Butyrophenone derivatives
FDA pharmacologic class
Atypical Antipsychotic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli52.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae41.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis65.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

6registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lumateperone Tosylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-10.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lumateperone Tosylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • ITI-007 (Lumateperone Tosylate) for Schizophrenia

    NCT03817528 · start 2019-03-01

    Registered record
    Registry ID
    NCT03817528
    Conditions
    Schizophrenia
    Interventions
    ITI-007
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2019-03-01
    Completion
    2020-09-23
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionITI-007
    PhasePhase 2
    Registry statusTerminated

  • Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally

    NCT03249376 · start 2017-11-27

    Registered record
    Registry ID
    NCT03249376
    Conditions
    Bipolar Depression
    Interventions
    Lumateperone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-11-27
    Completion
    2019-03-01
    Enrolment
    381

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Depression
    InterventionLumateperone; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression

    NCT02600507 · start 2016-03-07

    Registered record
    Registry ID
    NCT02600507
    Conditions
    Bipolar Depression
    Interventions
    Lumateperone (ITI-007); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-03-07
    Completion
    2020-07-02
    Enrolment
    529

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Depression
    InterventionLumateperone (ITI-007); Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment

    NCT02469155 · start 2015-06

    Registered record
    Registry ID
    NCT02469155
    Conditions
    Schizophrenia
    Interventions
    ITI-007; Risperidone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-06
    Completion
    2016-08
    Enrolment
    696

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionITI-007; Risperidone; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Trial to Assess the Antipsychotic Efficacy of ITI-007

    NCT02282761 · start 2014-11

    Registered record
    Registry ID
    NCT02282761
    Conditions
    Schizophrenia
    Interventions
    ITI-007; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-11
    Completion
    2015-09
    Enrolment
    450

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionITI-007; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Study of a Novel Antipsychotic ITI-007 in Schizophrenia

    NCT01499563 · start 2011-12

    Registered record
    Registry ID
    NCT01499563
    Conditions
    Schizophrenia
    Interventions
    ITI-007; Placebo; Risperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-12
    Completion
    2013-11
    Enrolment
    335

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionITI-007; Placebo; Risperidone
    PhasePhase 2
    Registry statusCompleted